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Chronic pain constitutes a major challenge in the healthcare field due 
to the difficulties and limitations of current treatments, and is considered 
a disease entity in its own right. In 2010, the American Society of 
Anesthesiologists defined chronic pain as “pain of any etiology not directly 
related to neoplastic involvement, associated with a chronic medical 
condition or extending in duration beyond the expected temporal boundary 
of tissue injury and normal healing, and adversely affecting the function or 
well-being of the individual”1. Global statistics show that 75–80% of people 
seek medical attention for pain and that 40% of adults suffer with some 
form of chronic pain2–5. Several studies have demonstrated an increased 
prevalence of chronic pain in women3–9. Pain perception also seems to differ 
between males and females, and in female mice, appears to vary during the 
estrous cycle10. 
Regarding treatment, chronic pain is difficult to manage, as it responds 
poorly to the conventional pharmacological armamentarium (NSAIDs and 
opioids) and thus requires a variety of alternative therapy strategies. This 
has led to countless investigations into nonpharmacological therapies and 
novel substances that can address this challenge. Among the substances 
researched for this purpose, melatonin has emerged as an interesting 
option for conditions that include disruption of the endogenous clock system 
associated with pain, inflammation, and changes in the sleep-wake cycle11. 
Gender differences in a variety of pain-related aspects have been an 
object of substantial research, both in humans12–14 and in animals15,16. 
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ABSTRACT
Chronic pain is a major public health problem that affects approximately 40% of the 
adult population worldwide. Several epidemiological studies have shown a higher 
prevalence of chronic pain in women, with variations within the menstrual cycle and 
an increase in pain after menopause. Clinical and experimental studies have shown 
differences in pain perception between genders, but the underlying mechanisms 
of this inequality are complex and far from being understood. Estrogens play an 
important role in pain modulation and seem to account at least partially for these 
differences. Melatonin is a neurohormone synthesized mainly by the pineal gland 
that regulates circadian rhythms and has anti-inflammatory, antioxidant, sedative, 
antidepressant, anxiolytic, and analgesic effects. After menopause, melatonin levels 
decrease, which may be the cause of the sleep disorders that usually affect women 
during this period of life. Some studies have demonstrated an interaction between 
melatonin and estrogens in terms of antioxidant effects. The present study seeks to 
provide a review on melatonin, estradiol, and chronic pain in women.
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Epidemiological studies have shown that women 
have a greater prevalence of disorders with 
a chronic pain component, such as migraine, 
temporomandibular joint dysfunction, arthritis, 
fibromyalgia, and interstitial cystitis; increased 
susceptibility to nociceptive stimuli; and more 
frequent analgesic use2–9,17. Clinical studies have 
shown an increased prevalence of pain disorders in 
women than in men, and experimental research has 
demonstrated gender differences in the functional 
and structural characteristics of pain pathways18. 
For instance, female rats are more susceptible 
to inflammatory pain and to development of 
neuropathic pain than males19–22. 
However, the effects of gender on pain 
processing and response and the mechanisms 
underlying these differences are complex and 
far from being understood23. Although genetic, 
environmental, social, and cultural factors must be 
taken into account, sex hormones unquestionably 
play a major role. Among them, estrogens, as the 
main female hormones, have received the most 
research attention15,24,25, but with contradictory 
results; some studies have reported pronociceptive 
action, while others found antinociceptive 
effects16,18,23,26,27. 
Menopause is known to affect pain, depending 
on its type and characteristics28. Estradiol has 
been shown to alter the pain system at various 
levels, such as inflammatory response, dorsal root 
ganglia, opioidergic and serotonergic systems, 
limbic circuits and stress responses14. Studies 
have demonstrated low melatonin levels in 
many diseases associated with chronic pain29,30. 
Furthermore, melatonin administration has been 
shown to improve chronic pain conditions in 
humans31–33. As chronic pain syndromes are known 
to change after menopause28 and both melatonin 
and estradiol levels decrease in postmenopausal 
years, it is important to study how these hormones 
can affect pain, although many others substances 
may be involved too34,35. Within this context, this 
review article seeks to address the effects of 
estradiol and melatonin on chronic pain during the 
postmenopausal period.
LITERATURE REVIEW
This review seeks to address the main aspects 
of postmenopausal chronic pain and elucidate 
its pathogenesis and the role of estradiol and 
melatonin. The MEDLINE (PubMed), LILACS, and 
SciELO databases were searched. Combining 
the search term “chronic pain” with “menopause”, 
“melatonin”, and “estradiol” yielded 58, 155, and 
108 articles, respectively. The search string “chronic 
pain” and “menopause” plus “melatonin” yielded 
only three articles, whereas a combination of all 
four search terms yielded none. Of the 421 articles 
identified in our initial search, 28 were duplicates. 
Of the 393 remaining articles, 68 were selected 
and included after a review of abstracts, and their 
references were hand-searched in an attempt to 
locate additional relevant studies not identified by 
our original search strategy.
CHRONIC PAIN
The International Association for the Study 
of Pain (IASP) defines pain as “an unpleasant 
sensory and emotional experience associated with 
actual or potential tissue damage, or described 
in terms of such damage”36. From a temporal 
perspective, there are two types of pain: acute and 
chronic. Acute pain lasts seconds, days or weeks 
and usually occurs as a signal of tissue damage, 
while chronic pain can last for months or years 
and not be associated with concomitant injury37. 
Chronic pain may be due to disorders of the 
systems responsible for both pain perception and 
pain inhibition. Basically, chronic pain is the result 
of long-lasting nociceptive stimuli or changes in the 
peripheral or central nervous system36. 
Depending on its pathogenesis, chronic pain 
may be classified as nociceptive or neuropathic. 
Nociceptive pain is the result of direct activation 
of nociceptors in response to tissue injury with 
concomitant inflammation, whereas neuropathic or 
neurogenic pain is the result of peripheral or central 
nerve injury37–39. Namely, chronic nociceptive pain 
occurs for long-lasting activation of nociceptors, 
as in chronic inflammatory diseases; while chronic 
neuropathic pain is characterized by spontaneous 
pain without any apparent stimulus38. 
In addition to neurophysiological phenomena, 
psychological, cognitive, behavioral, social, and 
cultural aspects modulate the experience of 
pain37,39. Several predisposing factors for chronic 
pain are known, including gender, age, psychosocial 
issues, underlying disease, type of nerve injury, 
and severity of inflammatory response. Factors 
specific to surgical cases include the use and type 
of preoperative analgesia, type and duration of 
surgery, and the intensity of acute postoperative 
pain40,41.  
Pain perception depends on specialized 
receptors (nociceptors) that are activated only 
when a stimulus reaches a noxious threshold and 
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that respond progressively in accordance with the 
intensity of the stimulus38. Continued stimulation may 
decrease the response threshold of nociceptors, in 
a process known as sensitization42–44. 
Myelinated A delta (Aδ) fibers respond to intense 
mechanical and thermal stimuli and are responsible 
for sharp, highly localized “first pain”, whereas 
unmyelinated C fibers respond to mechanical, 
thermal, and chemical stimuli and mediate the so-
called “second pain”, which is poorly localized and 
diffuse. These fibers are axons of primary afferent 
neurons known as first-order neurons42–44.
When a nociceptor is activated, the 
neurotransmitters glutamate, substance P, and 
calcitonin gene-related peptide (CGRP) are 
released at the synapse with the second-order 
neuron, in the spinal cord, and peripherally at 
the site of injury. Peripherally, neurotransmitters 
stimulate nociceptors to induce peripheral 
sensitization and produce the cardinal signs of 
inflammation: erythema, edema, pain, and loss of 
function38,43.
Substance P and CGRP stimulate histamine 
and bradykinin release by mast cells at the site 
of injury. CGRP also induces vasodilation, which 
increases the release of inflammatory molecules 
such as prostaglandins. These processes reduce 
the nociceptor activation threshold, producing 
hyperalgesia (an augmented response to a painful 
stimulus) and allodynia (perception of a non-
noxious stimulus as painful)38,42,44 (figure 1).
A delta and C fibers synapse at the posterior 
horn of the spinal cord, thus initiating the pain 
modulation process through descending pathways. 
The second-order neurons may be nociceptive-
specific (NS) neurons, which only synapse with A 
delta and C fibers, or wide dynamic range (WDR) 
neurons, which receive data from all sensory fiber 
types37,38.
After its integration at the spinal cord, 
nociceptive information is conveyed to the 
thalamus and thence to the somatosensory cortex. 
Each level of the central nervous system (CNS) 
contains pain-modulating mechanisms. N-methyl-
D-aspartate (NMDA) and opioid receptors, which 
are the two most important systems for modulation 
of nociception and antinociception respectively, are 
distributed across nearly all regions of the CNS37,38.
Modulatory mechanisms sensitize or suppress 
nociception at each of the “way stations” where it 
is processed. At the various stages of each pain 
pathway, different control systems constantly 
modulate both ascending and descending 
transmission  of nociceptive information37–39.
In the setting of severe or persistent injury, 
C fibers fire repeatedly, and the response of 
dorsal horn neurons increases gradually, leading 
to central sensitization by the so-called “wind-
up” phenomenon, which results from repetitive 
Figure 1: Neurophysiological mechanisms of chronic pain: central sensitization, peripheral 
responses, hyperalgesia, and allodynia. CGPR: calcitonin gene-related peptide.
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excitatory stimulation of WDR neurons by 
glutamate37,38,42. 
Peripheral and central sensitizations are 
mechanisms that amplify the noxious stimulus 
so as to evoke a protective behavioral response. 
However, when these mechanisms become 
maladjusted, they may induce permanent changes 
in the communication of pain pathways and, 
consequently, to the development of chronic 
pain38,44,45.
In addition to maladaptive peripheral and central 
sensitization, the loss of descending inhibition from 
the brainstem centers and periaqueductal gray 
(PAG), astrocyte and microglial activation, and 
direct signaling from neurons to glial cells may be 
responsible for the persistence of pain44,45.
MELATONIN
Melatonin is a neurohormone synthesized 
and released by the pineal gland that plays an 
important role in the regulation of circadian rhythms 
46,47. This hormone is derived from L-tryptophan 
and, in addition to a major chronobiological role in 
the regulation of neuroendocrine and physiologic 
functions, has several pharmacologic properties, 
including sedative, anxiolytic, antidepressant, 
antioxidant, anti-inflammatory, and analgesic 
actions48–54.
Melatonin is released during the dark period, and 
signals the start and end of this period. Therefore, it 
signals the alternating light-dark cycle and seasons 
of the year. The melatonin release profile provides 
a good measure of circadian phase. Its production 
begins to increase in the evening, peaks at 60–
100 times its baseline level in the early morning 
hours, and decreases gradually thereafter; this 
cycle is considered the hormonal expression of the 
biological clock55,56. 
The mechanisms of action of melatonin 
involve two transmembrane receptors (MT1 and 
MT2). A third cytosolic binding site (MT3) has 
been purified and characterized as the enzyme 
quinone reductase 2 (QR2)57. Inhibition of QR2 by 
melatonin may explain a protective effect which 
has been reported in several animal models and is 
associated with its antioxidant properties57.
MELATONIN AND ANTINOCICEPTION
The antinociceptive effect of melatonin is 
uniquely important. Several possible mechanisms 
have been proposed for the actions of melatonin on 
inflammatory and algogenic processes, including 
inhibition of nitric oxide production and reduced 
expression of the enzyme nitric oxide synthase, 
activation of the transcription factor NF-қB (nuclear 
factor kappa B), a reduction in prostaglandin levels 
and cyclooxygenase-2 expression, and decreased 
recruitment of polymorphonuclear leukocytes to 
the site of inflammation50 (figure 2).
Figure 2: Melatonin and antinociception: mechanisms involved. NO: nitric oxide. NOS: nitric 
oxide synthase. NF-kB: nuclear factor kappa B. PG: prostaglandin. COX2: cyclooxygenase-2.
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Glutamate, gamma-amino butyric acid (GABA), 
and, particularly, opioid neurotransmission appear 
to play a role in the analgesic effect of melatonin58. 
Studies using melatonin receptor antagonist 
support a role for its receptors in analgesia58,59. 
Investigators suggested that the antinociceptive 
effect of melatonin may involve activation of 
supraspinal centers and inhibition of the wind-up 
phenomenon60,61. This hypothesis is corroborated 
by data from experimental studies of acute and 
chronic pain, including inflammatory acute pain, 
in which melatonin was administered orally and 
intrathecally to rodents, and a dose-dependent 
antinociceptive effect was observed50,61,62. 
In addition to its analgesic effect, melatonin 
has effects on mood modulation and on the sleep-
wake cycle63. These multifaceted effects make 
melatonin an appealing therapy for conditions that 
involve disruption of the endogenous clock system 
and pain, inflammation, or changes in sleep-wake 
rhythms31. These effects were first observed in 
acute pain in humans54 and in experimental models 
of pain53. 
1. Experimental works on melatonin’s 
antinociceptive effect
Several researchers have demonstrated the 
antinociceptive effect of melatonin. The most 
frequently used animals for these studies are rats 
and mice.
Yu et al. (2000) evaluated the analgesic effects 
of intraperitoneal (i.p.) and intracerebroventricular 
(i.c.v.) administration of melatonin and found that 
on i.p. administration, melatonin (30, 60 and 120 
mg/kg) produced the antinociceptive effect in a 
dose-dependent manner, and when administered 
i.c.v., melatonin (0.25, 0.5 and 1 mg/kg) also 
resulted in dose-dependent antinociception. 
Moreover, 10 μg of naloxone injected i.c.v. to 
rats antagonized significantly the antinociceptive 
effect induced by i.p. melatonin. These authors 
concluded that melatonin has an analgesic effect in 
rats and the central nervous system (CNS) may be 
the primary site for melatonin to elicit the response, 
and the effect of melatonin is related to the central 
opioid system61. 
Models of chronic inflammatory pain induced 
by carrageen, latex or complete Freund’s 
adjuvant (CFA) injection have been used to test 
melatonin’s effect. Laste et al. (2012) assessed 
the effect of exogenous melatonin in a model of 
chronic inflammation induced by CFA in rats and 
found that melatonin had strong chronobiotic and 
antinociceptive effects11. In a model of chronic 
neuropathic pain, melatonin produced a blockade 
of thermal hyperalgesia, but not mechanical 
allodynia in mice64.
2. Clinical studies on melatonin’s analgesic 
effect
Korszun et al. (1999), in a case-control study, 
found significantly increased plasma melatonin 
levels in patients with fibromyalgia65. Their findings 
contradicted those of Wikner et al. (1998), who found 
that fibromyalgic patients had a melatonin secretion 
31% lower than that of healthy subjects during the 
hours of darkness29. Corroborating the hypothesis 
of melatonin involvement on fibromyalgia, Citera et 
al. (2010) reported improvements in pain, fatigue, 
and sleep quality in patients with fibromyalgia when 
a dose of 3 mg/day of melatonin was administered66. 
Recently, Zanette et al. performed a phase II, 
randomized, double-dummy, controlled trial to 
evaluate melatonin alone or in combination with 
amitriptyline for the management of fibromyalgia. 
Sixty-three female patients were randomized to 
receive only amitriptyline (25 mg), only melatonin 
(10 mg) or amitriptyline (25 mg) + melatonin (10 
mg) for a period of six weeks. Treatment with 
melatonin alone or in combination with amitriptyline 
significantly reduced pain on the Visual Analogue 
Scale when compared with amitriptyline alone. 
Moreover, melatonin’s ability to improve the function 
of the inhibitory endogenous pain-modulating 
system was demonstrated33. 
Two clinical trials also demonstrated the 
analgesic effect of melatonin on other chronic pain 
conditions such as temporomandibular disorders31 
and endometriosis32.
These findings raise the possibility that 
melatonin be used as an adjuvant in the treatment 
of pain.
MELATONIN IN POSTMENOPAUSAL WOMEN
There is ample evidence of the interaction of 
melatonin with other hormones, including sex 
hormones. Decreased melatonin secretion has 
been well documented in aging patients67,68. Recent 
studies revealed an association between sleep 
disorders and a decreased level of melatonin only 
in women in perimenopause69. Okatani, Morioka 
& Wakatsuki (2000) found a significant negative 
correlation between peak serum melatonin and 
estradiol levels in women aged 40 to 50 years, 
and found that daily administration of conjugated 
estrogens suppressed nighttime melatonin 
secretion in postmenopausal women70. Toffol et al. 
(2014), in a randomized, placebo-controlled trial of 
Effects of melatonin and estradiol on chronic pain 
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the effects of hormone replacement therapy (HRT) 
on serum melatonin levels, found a mean delay 
of 2 h 21 min in peak melatonin time (acrophase) 
among postmenopausal women after 6 months of 
HRT, but mean melatonin levels and mean duration 
of melatonin secretion did not differ between 
patients and controls71.
Blaicher et al. (2000), in a case-control study, 
investigated the interaction between melatonin, 
sex steroids, and the neuroendocrine system in 
postmenopausal women and found significantly 
lower melatonin levels in women with insomnia 
and those with obesity when compared with 
controls72. In 1997, Cagnacci et al. demonstrated 
that administration of melatonin increases cortisol 
levels in postmenopausal women, and that estradiol 
reverses this effect73. Melatonin supplementation in 
the postmenopausal period was suggested by Baxi 
et al. (2013) as a safe and powerful alternative to 
mitigate the increased oxidative stress caused by 
decreased estrogen levels74.
ESTRADIOL 
Estrogens are female sex steroid hormones. 
In humans, the most potent estrogen hormone is 
17-beta-estradiol (E2). The biological effects of 
estrogens are based on genomic mechanisms, 
mediated by their interactions with the nuclear 
receptors alpha (ER-α) and beta (ER-ß), but also 
by rapid, nongenomic mechanisms involving 
G-protein coupled receptors (GPCRs), which can 
activate intracellular signaling cascades. Nuclear 
and transmembrane estrogen receptors are 
biochemically identical and can work in tandem75–77.
Estradiol can effect all four known types of 
hormonal action: intracrine (regulation of vital 
activities within its cell of origin), autocrine 
(regulation of vital activity within cells involved in 
its formation, secretion, and reuptake), paracrine 
(regulation of vital activities in neighboring cells in 
the same tissue), and endocrine (influencing cells 
at remote organ)75. 
Estrogens regulate a wide range of cell functions. 
Originally identified as regulators of reproduction 
and sexual behavior alone, they are now known to 
affect the somatosensory system, and a possible 
action on pain processing at the spinal level has 
been suggested78.
Estradiol is produced not only in the ovaries and 
adrenal glands, but also in non-endocrine tissues 
such as the CNS and bone, where it plays important 
roles75. For instance, in experimental studies, 
estradiol has been shown to induce proliferation 
of hematopoietic stem cells79, protect against brain 
injury, neurodegeneration, and cognitive decline80.
It is well established that many of the actions of 
estrogens on the CNS are mediated by their nuclear 
receptor ER-ß, which interacts with response 
elements in steroid target genes (genomic action – 
slow). However, there is convincing evidence of the 
presence of transmembrane estrogen receptors 
(GPCRs) in hypothalamic neurons and other 
areas of the CNS (nongenomic action – rapid). 
Indeed, estrogens are able to rapidly alter neuronal 
activity (within seconds). Furthermore, estrogens 
can affect second-messenger systems involving 
calcium mobilization and kinase activation to alter 
cell signaling and contribute to homeostasis81–83.
ESTRADIOL AND ANTINOCICEPTION
1 . Experimental works on estradiol and 
antinociception
Various studies on sex differences in basal 
nociceptive sensitivity have been performed 
on animals, most of them rodents. Craft et al. 
(2008) showed that estradiol administration 
dose- and time-dependently alters sensitivity to 
the antinociceptive effects of morphine in female 
rats15. In an inflammatory pain model using 
complete Freund’s adjuvant (CFA), female rats 
developed inflammation more quickly and with 
greater peak hyperalgesia than males, with the 
lowest nociceptive thresholds seen in estrous and 
proestrous22.
Many authors have studied the effect of 
estradiol on pain modulation. Zhang et al. (2012), 
using electrophysiological, morphological, and 
biochemical methods, demonstrated that estradiol 
can directly modulate spinal cord synaptic 
transmission by enhancing NMDA receptors 
in dorsal horn neurons, increasing glutamate 
release from primary afferent terminals, and 
increasing dendritic density in cultured spinal cord 
neurons24. The presence of estrogen receptors in 
the PAG suggests that estrogen hormones can 
influence descending pain modulation pathways 
– a hypothesis supported by studies showing that 
female rats in estrous are less sensitive than those 
in diestrus to antinociception induced by intra-PAG 
morphine injection; furthermore, female rats are 
more susceptible than males to the reduction in 
antinociception induced by irreversible blockade of 
µ-opioid receptors in the PAG84.
2.  Human studies on estradiol and chronic pain
Moreira et al
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The main sex difference with respect to pain is 
the greater prevalence of chronic pain syndromes 
in women as compared to men6. Irritable bowel 
syndrome (IBS), fibromyalgia, temporomandibular 
disorder (TMD), and chronic headaches are more 
frequent in females than in males5,6. In addition, 
the incidence of less well-defined chronic pain 
conditions such as fibromyalgia peaks around 
menopause85. Postmenopausal women are twice 
more likely to experience joint pain or stiffness than 
premenopausal women86. 
The discovery of gender differences in 
nociceptive response implies that sex steroids 
modulate sensitivity to analgesic drugs and to 
environmental stimuli involving the neurobiological 
systems that play a role in the pain perception 
process. As estrogens can influence the function 
of several body systems, including the nervous, 
immune, musculoskeletal, and cardiovascular 
systems, estrogenic pain modulation is exceedingly 
complex, alternating between pro-nociceptive and 
antinociceptive effects, depending on the extent to 
which each of these systems is involved and on the 
type of pain.
INTERACTION BETWEEN MELATONIN AND 
ESTRADIOL
Several studies have shown that both melatonin 
and estradiol have antioxidant effects, and some 
of these studies have confirmed the analgesic 
and anti-inflammatory actions of melatonin50,52,53,87. 
Regarding estradiol, however, studies are still 
conflicting.  
In addition to Cagnacci et al., who demonstrated 
that melatonin administration increases cortisol 
levels in postmenopausal women and that this effect 
is reversed by estradiol73, Kerdelhué et al. (2006) 
also studied the interaction among melatonin, 
estradiol, and cortisol. These authors found a rapid, 
significant decline in serum cortisol levels after 
intramuscular administration of estradiol valerate 
at 8:00 a.m. in postmenopausal women. However, 
they found only a nonsignificant decrease in serum 
melatonin levels88. 
In 2012, Karadayian et al. studied the interaction 
between estradiol and melatonin in mice subjected 
to a behavioral model of ethanol-induced hangover 
and found that estrogen interferes by blocking the 
protective action on motor performance conferred 
by melatonin during a hangover89. Another 
experimental study found an increase in the 
antioxidant effect of estradiol when combined with 
melatonin90.
CONCLUSION
The transition from reproductive to menopausal 
status induces several physiological adjustments 
involving all body organs and their functions. 
These modifications are believed to relate mostly 
to hormonal changes, mainly to the decrease 
of estradiol, the leading hormonal alteration in 
postmenopausal women. Melatonin secretion 
was also shown to change in perimenopausal and 
postmenopausal years and to affect and be affected 
by estradiol levels. Another condition that is known 
to change with menopause is chronic pain. Most of 
the painful disorders where the analgesic properties 
of melatonin have been investigated are known to 
be more prevalent in women, and to be affected by 
menopause, such as fibromyalgia, chronic arthritis, 
IBS and TMD. Studies have demonstrated a close 
interaction between estradiol and melatonin. 
Therefore, further research into the involvement 
of these two hormones on nociceptive processes 
is required to advance our understanding of the 
pathways involved in pain modulation and to 
establish sex-tailored therapies to chronic painful 
disorders. 
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